nemonoxacin malate
Commercial- Indications
- Infection
Company intelligence / Profile preview
Zhejiang Medical Technology Development
Zhejiang Sheng / Province, China
- Ownership
- Private
- Employees
- ~50
- Development stage
- Commercial
01
Overview
Zhejiang Medical Technology Development has an active pipeline with at least one approved small molecule drug ("Glycerol phenylbutyrate" for urea cycle disorders) and another candidate ("Difelikefalin acetate") in Phase 3 trials targeting pruritus via the κ opioid receptor. The company focuses on hospital acute care, gastroenterology, and oncology market segments.
- Therapeutic areas
- Metabolic DisordersDermatology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Zhejiang Medical Technology Development.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zhejiang Medical Technology Development.